Abstract
Coronavirus is able to affect various organs and systems including the immune system. At the same time, the state of the immune system may be initially changed in patients with pre-existing comorbid non-infectious disorders. The aim of our study was to evaluate biochemical and immunological markers of adverse outcomes in the patients with new coronavirus infection with underlying arterial hypertension.
The retrospective study included 47 patients with COVID-19 and arterial hypertension, who underwent a study of C-reactive protein (CRP), interleukin-6 (IL-6), assessing the increased values of these markers and the outcomes of the disease. The study group included 23 male and 24 female patients at the median age of 54 (for men), and 57 years old (for women).
Upon admittance of the patients with COVID-19 and hypertension to the hospital, a parallel increase in both CRP and IL-6 was registered in these cases. Statistically significant differences were found in the levels of CRP and IL-6 in patients with a favorable versus unfavorable clinical outcomes. The levels of CRP and IL-6 in deceased patients were higher and did not tend to decrease. Thus, the simultaneous increase in CRP and IL-6 in patients with COVID-19 and hypertension is considered an unfavorable prognostic parameter for patients’ survival.
Publisher
Russian Society of Immunology
Subject
Immunology,General Medicine
Reference8 articles.
1. Антипова Е.П., Моисеева М.В., Багишева Н.В., Мордык А.В., Джусоева Е.Г., Стрельцова В.В. COVID-19 в когорте пациентов с артериальной гипертензией: роль рецепторов ангиотензинпревращающего фермента // Забайкальский медицинский вестник, 2023. № 1. С. 104-112. [Antipova E.P., Moiseeva M.V., Bagisheva N.V., Mordyk A.V., Dzhusoeva E.G., Streltsova V.V. COVID-19 in a cohort of patients with arterial hypertension: the role of angiotensin-converting enzyme receptors. Zabaykalskiy meditsinskiy vestnik = Transbaikal Medical Bulletin, 2023, no. 1, pp. 104-112. (In Russ.)]
2. Моисеева М.В., Багишева Н.В., Мордык А.В., Джусоева Е.Г., Антипова Е.П., Марченко Е.Д. Что известно о влиянии артериальной гипертензии на течение COVID-19 // Клинический разбор в общей медицине, 2022. № 5. С. 6-9. [Moiseeva M.V., Bagisheva N.V., Mordyk A.V., Dzhusoeva E.G., Antipova E.P., Marchenko E.D. What is known about the effect of arterial hypertension on the course of COVID-19. Klinicheskiy razbor v obshchey meditsine = Clinical Analysis in General Medicine, 2022, no. 5, pp. 6-9. (In Russ.)]
3. Насонов Е.Л. Иммунопатология и иммунофармакотерапия коронавирусной болезни 2019. (COVID-19): фокус на интерлейкин 6 // Научно-практическая ревматология, 2020. Т. 58, № 3. С. 245-261. [Nasonov E.L. Immunopathology and immunopharmacotherapy of coronavirus disease 2019. (COVID-19): focus on interleukin 6. Nauchno-prakticheskaya revmatologiya = Scientific and Practical Rheumatology, 2020, Vol. 58, пo. 3, pp. 245-261. (In Russ.)]
4. Aziz M., Fatima R., Assaly R. Elevated interleukin-6 and severe COVID-19: A meta- analysis. J. Med. Virol., 2020, Vol. 92, no. 11, pp. 2283-2285.
5. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)